Phosphoinositide 3-kinase as a therapeutic target in angiogenic disease.
Akt
Angiogenesis
Inflammation
Isoform inhibitors
PI3K
Journal
Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
22
06
2022
revised:
30
08
2023
accepted:
05
09
2023
medline:
13
11
2023
pubmed:
17
9
2023
entrez:
16
9
2023
Statut:
ppublish
Résumé
Phosphoinositide 3-kinases (PI3Ks) generate lipids that control multitudinous intracellular cell signaling events which participate in cell survival and proliferation. In addition, PI3K signaling also contributes to metabolism, immunity, angiogenesis and cardiovascular homeostasis, and many diseases. The diverse actions of PI3K stem from the existence of their various isoforms and a variety of protein effectors. Hence, PI3K isoform-specific inhibitors have already achieved a wonderful effect on treating cancer. Herein, we summarize the molecular mechanism of PI3K inhibitors in preventing the permeability of vessels and neovascularization. Additionally, we briefly illustrate how PI3K signaling modulates blood vessel growth and discuss the different roles that PI3K isoforms play in angiogenesis.
Identifiants
pubmed: 37716399
pii: S0014-4835(23)00267-1
doi: 10.1016/j.exer.2023.109646
pii:
doi:
Substances chimiques
Phosphatidylinositol 3-Kinase
EC 2.7.1.137
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Phosphoinositide-3 Kinase Inhibitors
0
Protein Isoforms
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109646Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.